About PepGen Inc.
https://www.pepgen.comPepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD).
CEO
James G. McArthur
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 24
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:20.06M
Value:$103.33M
VIKING GLOBAL INVESTORS LP
Shares:3.48M
Value:$17.93M
COMMODORE CAPITAL LP
Shares:2.36M
Value:$12.14M
Summary
Showing Top 3 of 76
About PepGen Inc.
https://www.pepgen.comPepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $18.32M ▼ | $-18.03M ▲ | 0% | $0.55 ▲ | $-17.69M ▲ |
| Q2-2025 | $0 | $23.93M ▼ | $-23.09M ▲ | 0% | $-0.7 ▲ | $-22.66M ▲ |
| Q1-2025 | $0 | $31.32M ▲ | $-30.2M ▼ | 0% | $-0.92 ▼ | $-30M ▼ |
| Q4-2024 | $0 | $23.96M ▲ | $-22.24M ▼ | 0% | $-0.68 ▼ | $-22.48M ▼ |
| Q3-2024 | $0 | $23.17M | $-21.38M | 0% | $-0.66 | $-21.86M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $163.66M ▲ | $190.06M ▲ | $26.92M ▼ | $163.14M ▲ |
| Q2-2025 | $74.65M ▼ | $102.24M ▼ | $31.08M ▼ | $71.16M ▼ |
| Q1-2025 | $97.78M ▼ | $127.39M ▼ | $35.59M ▲ | $91.81M ▼ |
| Q4-2024 | $120.19M ▼ | $150.88M ▼ | $32.26M ▼ | $118.62M ▼ |
| Q3-2024 | $138.86M | $170.23M | $32.78M | $137.46M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-18.03M ▲ | $-19.26M ▲ | $18.9M ▲ | $108.05M ▲ | $107.7M ▲ | $-19.36M ▲ |
| Q2-2025 | $-23.09M ▲ | $-23.6M ▼ | $14.96M ▼ | $98K ▲ | $-8.56M ▼ | $-23.64M ▼ |
| Q1-2025 | $-30.2M ▼ | $-22.93M ▼ | $17.15M ▼ | $0 ▼ | $-5.79M ▼ | $-23.05M ▼ |
| Q4-2024 | $-22.24M ▼ | $-19.48M ▲ | $26.5M ▲ | $128K ▼ | $7.13M ▲ | $-19.7M ▲ |
| Q3-2024 | $-21.38M | $-24.01M | $-133K | $327K | $-23.8M | $-24.2M |
CEO
James G. McArthur
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 24
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:20.06M
Value:$103.33M
VIKING GLOBAL INVESTORS LP
Shares:3.48M
Value:$17.93M
COMMODORE CAPITAL LP
Shares:2.36M
Value:$12.14M
Summary
Showing Top 3 of 76